LAUSR

Larotrectinib OK'd for Cancers with TRK Fusions.

Sign Up to like & get
recommendations!
1 Published in 2019 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-nb2018-163

Abstract: Larotrectinib, a first-in-class TRK inhibitor, received accelerated approval for patients of all ages with solid tumors harboring NTRK fusions. It's the first tissue-agnostic marketing authorization for a targeted therapy and the first time a drug's… read more here.

Keywords: cancers trk; larotrectinib cancers; trk fusions;